Rana R. McKay, MD

Rana R. McKay, MD, FASCO, is a professor in the Department of Medicine and Department of Urology at the University of California, San Diego Health.

Articles

Final Thoughts: Importance of Treating mCSPC and Preserving Quality of Life

August 13th 2025

Panelists discuss how successful metastatic castration-sensitive prostate cancer (mCSPC) management requires balancing cancer control with quality-of-life preservation, emphasizing the need for better tools to measure patient-reported outcomes, comprehensive survivorship care addressing cardiovascular and bone health, and personalized approaches that help patients understand their prognosis while maintaining their ability to thrive during treatment.

Weighing HRQOL and Tolerability in Metastatic Castration-Sensitive Prostate Cancer Care

August 6th 2025

Panelists discuss how quality-of-life considerations are paramount in treatment selection for patients with metastatic castration-sensitive prostate cancer (mCSPC), with data showing that achieving ultralow prostate-specific antigen (PSA) levels correlates with better quality-of-life outcomes and that tolerability profiles, particularly regarding fatigue and drug-drug interactions, significantly impact daily patient experience.

Suboptimal PSA Response: What Are the Best Next Steps?

August 6th 2025

Panelists discuss how managing patients with suboptimal prostate-specific antigen (PSA) response or rising PSA requires careful consideration of PSA kinetics, doubling time, duration of prior response, and imaging findings to determine whether to continue monitoring, add therapy, or transition to castration-resistant treatment approaches.

Dr McKay on the Role of Casdatifan Plus Cabozantinib in Clear Cell RCC

August 4th 2025

Rana R. McKay, MD, FASCO, details the significance of casdatifan plus cabozantinib demonstrating better responses vs the respective agents alone in ccRCC.

Understanding PSA Threshold in Metastatic Castration-Sensitive Prostate Cancer

July 30th 2025

Panelists discuss how data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) demonstrates that achieving a prostate-specific antigen (PSA) threshold below 0.2 ng/mL at 6 to 12 months is associated with improved progression-free survival and overall survival regardless of treatment regimen.

PSA Nadir and Response Assessment in Metastatic Castration-Sensitive Prostate Cancer

July 30th 2025

Panelists discuss how prostate-specific antigen (PSA) nadir serves as a crucial prognostic marker in metastatic castration-sensitive prostate cancer (mCSPC), with faster drops to lower levels (particularly below 0.2) correlating with better outcomes, whereas imaging frequency should be customized based on clinical status and PSA kinetics.

Key Takeaways in mCSPC: Combination Therapy and Germline Testing Is the New Standard of Care

July 23rd 2025

Panelists discuss how androgen deprivation therapy (ADT) monotherapy is no longer acceptable for metastatic castration-sensitive prostate cancer (mCSPC), emphasizing that combination therapy with androgen receptor (AR) pathway inhibitors or chemotherapy plus universal germline testing should be the new standard of care.

Expert Perspectives: ARANOTE: Subgroup Analysis in Black Patients

July 23rd 2025

Panelists discuss how the ARANOTE trial’s subgroup analysis of 65 Black patients (primarily from Brazil and South Africa) demonstrated consistent treatment benefits and highlights the importance of diversity in clinical trials to address health care disparities and potential biological differences across populations.

Interpreting ARANOTE: Darolutamide in Doublet and Triplet Therapy for Metastatic Castration-Sensitive Prostate Cancer

July 16th 2025

Panelists discuss how the ARANOTE trial’s progression-free survival benefits with darolutamide inform treatment selection between doublet and triplet approaches, emphasizing personalized decision-making based on tumor burden, patient performance status, and the “first shot, best shot” treatment philosophy.

Long-Term Efficacy of Doublets—the ARCHES 5-Year Update

July 16th 2025

Panelists discuss how the ARANOTE trial’s quality-of-life data and the ARCHES trial’s 5-year follow-up demonstrate sustained benefits of doublet therapy, with enzalutamide plus ADT showing a 3-year overall survival improvement in high-volume patients.

Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field toward increasingly complex, biomarker-driven treatment selection.

Choosing a Chemotherapy-Based Triplet Regimen in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.

Patient Fitness and the Doublet vs Triplet Debate in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.

Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.

Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

March 4th 2024

Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

March 4th 2024

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.

Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

February 26th 2024

This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.

Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

February 26th 2024

Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

February 19th 2024

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

February 19th 2024

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice